Andrew McKee shares insights about the differences between US and Japan innovation and output in the Biopharma industry. As we’ve expanded our US-Japan services, we are often asked about the differences between the US and Japanese biopharma industry. There are several, and we recently hosted a members-only webinar in Japan about the differences between US and JP innovation and output.  Japan is, of course, a growing leader in biopharma and home to several top multinationals. Japan consistently ranks highly among…

Andrew McKee shares an article that explains the benefits of prioritizing research and development initiatives, especially in today’s market. As our economy continues to change, we thought it would be helpful to share some insights and industry patterns that we have experienced with our clients. One critical investment that we don’t see enough of in an economic downturn is portfolio prioritization and portfolio strategy. It is inevitable for us to feel reserved and apprehensive about our businesses as our economy…

Storytelling may be a current buzzword but that doesn’t belittle the efficacy of telling a good story. Andrew McKee shares his company’s approach to spinning a good yarn for a slide deck. Biotech’s flameout,” “bloodbath,” “thousands of layoffs.” We’ve all heard it, and we’re in it. Whether you’re at a company looking to build alignment with your Board on how to conserve cash, searching for optimal partners to support clinical milestones, developing strategies to attract sought-after VC funds, or in…

In this article, Andrew McKee identifies the top five uncertainties his company tackles when creating revenue forecast models. One of our most sought-after commercial strategy services is the creation of revenue forecasts. As such, we’ve spent numerous projects ruminating on the most influential uncertainties in building revenue forecasts, and how to best converge on a reliable estimate. We’ll share our thoughts below, and hope they are helpful, whether in assisting you in building out your forecast or understanding our approach…

Andrew McKee shares an article on the latest developments in Ulcerative Colitis.  Many of our clients are pursuing groundbreaking therapies in disease areas with high unmet medical needs, giving our firm the chance to become intimately familiar with some of the most exciting areas in drug development.  One disease area that is receiving a lot of attention is Inflammatory Bowel Disease (IBD), where the disease burden and the need for novel, efficacious therapeutics remain high.  Below, we’ll share our thoughts…

Umbrex is pleased to welcome Andrew McKee with Headland Strategy Group. Andrew has 15 years’ experience in biotechnology, pharmaceuticals, diagnostics, and other healthcare sectors. In his health care work, he specializes in consulting projects for healthcare executives that combine disruptive growth strategy expertise (e.g., disease area strategy, pipeline marketing/commercial evaluations, novel disruptive technologies) with distinctive consulting offerings (e.g., strategic decision-making workshop design and facilitation; qualitative market research with thought leaders). These projects necessarily require Andrew and his team to be…